These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 11573104)

  • 1. Giant cell myocarditis, in a patient with Crohn's disease, treated with etanercept--a tumour necrosis factor-alpha antagonist.
    Nash CL; Panaccione R; Sutherland LR; Meddings JB
    Can J Gastroenterol; 2001 Sep; 15(9):607-11. PubMed ID: 11573104
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transcending conventional therapies: the role of biologic and other novel therapies.
    Sandborn WJ
    Inflamm Bowel Dis; 2001 May; 7 Suppl 1():S9-16. PubMed ID: 11380043
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New concepts in anti-tumor necrosis factor therapy for inflammatory bowel disease.
    Sandborn WJ
    Rev Gastroenterol Disord; 2005; 5(1):10-8. PubMed ID: 15741928
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel, etanercept) in patients with advanced heart failure.
    Deswal A; Bozkurt B; Seta Y; Parilti-Eiswirth S; Hayes FA; Blosch C; Mann DL
    Circulation; 1999 Jun; 99(25):3224-6. PubMed ID: 10385494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of etanercept for treatment of Crohn's related spondyloarthritis but not colitis.
    Marzo-Ortega H; McGonagle D; O'Connor P; Emery P
    Ann Rheum Dis; 2003 Jan; 62(1):74-6. PubMed ID: 12480676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Crohn's disease: future anti-tumor necrosis factor therapies beyond infliximab.
    Korzenik JR
    Gastroenterol Clin North Am; 2004 Jun; 33(2):285-301, ix. PubMed ID: 15177539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Etanercept in the treatment of active refractory Crohn's disease: a single-center pilot trial.
    D'Haens G; Swijsen C; Noman M; Lemmens L; Ceuppens J; Agbahiwe H; Geboes K; Rutgeerts P
    Am J Gastroenterol; 2001 Sep; 96(9):2564-8. PubMed ID: 11569676
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of Tumor Necrosis Factor Alpha Inhibitors for Inflammatory Bowel Disease Patients with Concurrent Heart Failure.
    Jiang Y; Lin O; Sinha SR
    Dig Dis Sci; 2017 Jun; 62(6):1597-1606. PubMed ID: 28417241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Psoriasis induced by tumor necrosis factor-alpha antagonist therapy: a case series.
    Cohen JD; Bournerias I; Buffard V; Paufler A; Chevalier X; Bagot M; Claudepierre P
    J Rheumatol; 2007 Feb; 34(2):380-5. PubMed ID: 17013997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cerebrovascular events in inflammatory bowel disease patients treated with anti-tumour necrosis factor alpha agents.
    Karmiris K; Bossuyt P; Sorrentino D; Moreels T; Scarcelli A; Legido J; Dotan I; Naismith GD; Jussila A; Preiss JC; Kruis W; Li AC; Bouguen G; Yanai H; Steinwurz F; Katsanos KH; Subramaniam K; Tarabar D; Zaganas IV; Ben-Horin S;
    J Crohns Colitis; 2015 May; 9(5):382-9. PubMed ID: 25740813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emergence of Crohn's disease during treatment with the anti-tumor necrosis factor agent etanercept for ankylosing spondylitis: possible mechanisms of action.
    Haraoui B; Krelenbaum M
    Semin Arthritis Rheum; 2009 Dec; 39(3):176-81. PubMed ID: 18706681
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of Crohn's disease following anti-tumour necrosis factor therapy (etanercept).
    Yazisiz V; Avci AB; Erbasan F; Yildirim B; Terzioğlu E
    Colorectal Dis; 2008 Nov; 10(9):953-4. PubMed ID: 18294265
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity.
    van Herwaarden N; den Broeder AA; Jacobs W; van der Maas A; Bijlsma JW; van Vollenhoven RF; van den Bemt BJ
    Cochrane Database Syst Rev; 2014 Sep; (9):CD010455. PubMed ID: 25264908
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Anti-TNF therapy in treatment of luminal Crohn's disease].
    Marko B; Prka L
    Acta Med Croatica; 2013 Apr; 67(2):179-89. PubMed ID: 24471301
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Manifestation of Crohn's disease in a young woman during the course of treatment for severe form of chronic plaque psoriasis with etanercept.
    Tichy M; Hercogova J
    Dermatol Ther; 2014; 27(4):211-4. PubMed ID: 24548537
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paradoxical articular manifestations in patients with inflammatory bowel diseases treated with infliximab.
    Thiebault H; Boyard-Lasselin P; Guignant C; Guillaume N; Wacrenier A; Sabbagh C; Rebibo L; Brazier F; Meynier J; Nguyen-Khac E; Dupas JL; Goëb V; Fumery M
    Eur J Gastroenterol Hepatol; 2016 Aug; 28(8):876-81. PubMed ID: 27101404
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunomodulatory effects of etanercept (TNFR:Fc) and its use in a patient with Crohn's disease.
    Srivastava MD
    Res Commun Mol Pathol Pharmacol; 2001 Jul; 109(1-2):125-41. PubMed ID: 11458980
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Approach to corticosteroid-dependent and corticosteroid-refractory Crohn's disease.
    Lichtenstein GR
    Inflamm Bowel Dis; 2001 May; 7 Suppl 1():S23-9. PubMed ID: 11380040
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease in Patients Naïve to or Who Have Failed Tumor Necrosis Factor Antagonist Therapy.
    Sands BE; Sandborn WJ; Van Assche G; Lukas M; Xu J; James A; Abhyankar B; Lasch K
    Inflamm Bowel Dis; 2017 Jan; 23(1):97-106. PubMed ID: 27930408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Efficacy of tumor necrosis factor-alpha inhibitors in fistulising perianal Crohn's disease].
    Bor R; Farkas K; Bálint A; Szűcs M; Abrahám S; Baradnay G; Wittmann T; Szepes Z; Nagy F; Molnár T
    Orv Hetil; 2013 Dec; 154(49):1943-8. PubMed ID: 24292112
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.